retatrutide phase 3 trial dosing schedule Eli Lilly's clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Retatrutide Dosing: Early Clinical Trial

By adding Wegovy to their Medicare formularies, plans may experience higher patient satisfaction ratings in their CAHPS (Consumer Assessment of Healthcare Providers and Systems) surveys in Rating of Drug Plans (D05 measure) and Getting Needed Prescription Drug (D06 measure)

For more such Replying to @thebigbulldeals#Shaily Engineering Plastics -Strong Growth Play in High-Margin Healthcare & Plastics

Ozempic is approved to treat type 2 diabetes Wegovy is specifically approved for chronic weight management In some cases, providers may prescribe Ozempic off-label for weight management when appropriate, but Wegovy is the formulation designed and approved for weight loss

The fact that patients in this trial continued to lose weight after gastrointestinal adverse effects had subsided suggests that these effects were not the cause of weight loss